Skip to main content

Table 10 Promoter CpG dinucleotide methylation of different genes in CML patients and association with molecular response

From: Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival

Gene

Response

Unmethylated (%)

Methylated (%)

Chi-Square

p-value

RASSF1

Optimal

98 (89.9%)

11 (10.1%)

13.35

0.001

Warning

13(72.2%)

5 (27.8%)

Failure

14 (60.9%)

9 (39.1%)

SOCS1

Optimal

101(92.6%)

8(7.4%)

0.94

0.62

Warning

16(88.9%)

2(11.1%)

Failure

20(86.9%)

3(13.1%)

DAPK1

Optimal

72 (66.0%)

37(34.0%)

2.80

0.24

Warning

9(50.0%)

9(50.0%)

Failure

12(52.2%)

11(47.8%)

RIZ1

Optimal

107(98.2%)

2(1.8%)

38.28

 < 0.001

Warning

13(72.2%)

5(27.8%)

Failure

13(56.5%)

10(43.5%)

P16INK4A

Optimal

86(79.0%)

23(21.0%)

25.16

 < 0.0001

Warning

11(61.1%)

7(38.9%)

Failure

6(26.1%)

17(73.9%)

P14ARF

Optimal

101(92.7%)

8(7.3%)

10.63

0.005

Warning

12(66.7%)

6(33.3%)

Failure

19(82.6%)

4(17.4%)